mtmt
Magyar Tudományos Művek Tára
XML
JSON
Átlépés a keresőbe
In English
Idézők
/
Idézések
Rewired Metabolism Caused by the Oncogenic Deregulation of MYC as an Attractive Therapeutic Target in Cancers
Vízkeleti, L. [Vízkeleti, Laura (molekuláris bioló...), szerző] Bioinformatika Tanszék (SE / AOK / I)
;
Spisák, S. ✉ [Spisák, Sándor (Molekuláris genetika), szerző] Enzimológiai Intézet (TTK)
Angol nyelvű Összefoglaló cikk (Folyóiratcikk) Tudományos
Megjelent:
CELLS 2073-4409
12
(13)
Paper: 1745
, 25 p.
2023
SJR Scopus - Biochemistry, Genetics and Molecular Biology (miscellaneous): Q1
Azonosítók
MTMT: 34075115
DOI:
10.3390/cells12131745
WoS:
001028514400001
Scopus:
85164715646
PubMed:
37443779
Támogatások:
(K-142835) Támogató: NKFI
MYC is one of the most deregulated oncogenes on multiple levels in cancer. As a node transcription factor, MYC plays a diverse regulatory role in many cellular processes, including cell cycle and metabolism, both in physiological and pathological conditions. The relentless growth and proliferation of tumor cells lead to an insatiable demand for energy and nutrients, which requires the rewiring of cellular metabolism. As MYC can orchestrate all aspects of cellular metabolism, its altered regulation plays a central role in these processes, such as the Warburg effect, and is a well-established hallmark of cancer development. However, our current knowledge of MYC suggests that its spatial- and concentration-dependent contribution to tumorigenesis depends more on changes in the global or relative expression of target genes. As the direct targeting of MYC is proven to be challenging due to its relatively high toxicity, understanding its underlying regulatory mechanisms is essential for the development of tumor-selective targeted therapies. The aim of this review is to comprehensively summarize the diverse forms of MYC oncogenic deregulation, including DNA-, transcriptional- and post-translational level alterations, and their consequences for cellular metabolism. Furthermore, we also review the currently available and potentially attractive therapeutic options that exploit the vulnerability arising from the metabolic rearrangement of MYC-driven tumors. © 2023 by the authors.
Idézők (3)
Idézett közlemények (4)
Hivatkozás stílusok:
IEEE
ACM
APA
Chicago
Harvard
CSL
Másolás
Nyomtatás
2025-04-14 07:00
×
Lista exportálása irodalomjegyzékként
Hivatkozás stílusok:
IEEE
ACM
APA
Chicago
Harvard
Nyomtatás
Másolás